IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.134
AS - Asia 1.375
EU - Europa 1.077
SA - Sud America 206
Continente sconosciuto - Info sul continente non disponibili 102
AF - Africa 92
OC - Oceania 3
Totale 4.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.080
CN - Cina 490
SG - Singapore 339
IE - Irlanda 315
VN - Vietnam 188
HK - Hong Kong 163
BR - Brasile 156
RU - Federazione Russa 153
DE - Germania 133
IT - Italia 123
FI - Finlandia 103
ZA - Sudafrica 74
FR - Francia 66
IN - India 56
GB - Regno Unito 49
CA - Canada 30
BD - Bangladesh 26
JP - Giappone 26
SE - Svezia 25
PL - Polonia 18
ES - Italia 15
CO - Colombia 14
AT - Austria 13
NL - Olanda 13
IQ - Iraq 12
MX - Messico 12
AR - Argentina 11
TR - Turchia 10
LT - Lituania 9
PK - Pakistan 8
SA - Arabia Saudita 8
CL - Cile 7
ID - Indonesia 7
PH - Filippine 6
AL - Albania 5
CZ - Repubblica Ceca 5
VE - Venezuela 5
BE - Belgio 4
BO - Bolivia 4
EC - Ecuador 4
EG - Egitto 4
GR - Grecia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
LV - Lettonia 3
MA - Marocco 3
PT - Portogallo 3
UA - Ucraina 3
AM - Armenia 2
BG - Bulgaria 2
CR - Costa Rica 2
DK - Danimarca 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
KR - Corea 2
LB - Libano 2
LU - Lussemburgo 2
MN - Mongolia 2
MU - Mauritius 2
MY - Malesia 2
PE - Perù 2
UY - Uruguay 2
UZ - Uzbekistan 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HN - Honduras 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
VG - Isole Vergini Britanniche 1
Totale 4.887
Salva come PNG Salva come JPEG
Città #
Dublin 313
San Jose 241
Ashburn 220
Chandler 208
Dallas 193
Singapore 191
Hong Kong 157
Beijing 146
Los Angeles 80
Helsinki 77
Boardman 76
Council Bluffs 75
Ho Chi Minh City 72
Johannesburg 70
Nanjing 55
New York 53
Munich 49
Lauterbourg 45
Hanoi 43
Shanghai 36
Princeton 35
Lawrence 34
Medford 33
Pavia 27
Wilmington 26
Tokyo 24
Milan 23
Santa Clara 23
Moscow 21
Nanchang 21
Orem 20
Jacksonville 19
São Paulo 19
Chennai 18
Redondo Beach 18
Buffalo 17
Changsha 16
Montreal 16
Piscataway 15
Shenyang 15
Warsaw 15
Chicago 14
Da Nang 14
Hebei 14
Turku 14
Atlanta 13
Nuremberg 13
Tianjin 13
Denver 12
Frankfurt am Main 10
Haiphong 10
Jiaxing 10
Poplar 10
San Francisco 10
Stockholm 10
Falkenstein 9
Houston 9
London 9
Amsterdam 8
Ankara 8
Brooklyn 8
Norwalk 8
Pune 8
Seattle 8
Vienna 8
Columbus 7
Hangzhou 7
Hải Dương 7
Manchester 7
Phoenix 7
Toronto 7
Mexico City 6
Rio de Janeiro 6
Tamm 6
The Dalles 6
Woodbridge 6
Cagliari 5
Catania 5
Fairfield 5
Hyderabad 5
Padua 5
Redwood City 5
Tirana 5
Baghdad 4
Bexley 4
Boston 4
Brasília 4
Brussels 4
City of London 4
Riyadh 4
Rome 4
Washington 4
Agawam 3
Amman 3
Athens 3
Baku 3
Biên Hòa 3
Bogotá 3
Brno 3
Charleston 3
Totale 3.272
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 217
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 141
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 140
A patient with AL amyloidosis with negative free light chain results 129
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 126
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
Prognostication of survival and progression to dialysis in AA amyloidosis 116
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 112
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 110
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 109
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 109
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 108
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 107
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 103
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 102
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 99
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 98
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 96
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 92
A case of monoclonal gammopathy of renal significance 92
Development and Validation of Staging Systems for AA Amyloidosis 86
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 86
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 85
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 85
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 84
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 82
The lung in amyloidosis 80
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 79
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 77
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 75
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 73
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 70
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 68
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 68
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 66
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 65
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 61
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 56
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 52
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 52
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 45
Renal amyloidoses 41
null 33
null 30
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis 29
null 29
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study 26
null 6
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS 1
Totale 4.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022152 0 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025864 27 57 9 28 10 75 79 35 210 50 107 177
2025/20262.301 147 149 193 308 319 85 389 144 253 142 69 103
2026/2027242 175 67 0 0 0 0 0 0 0 0 0 0
Totale 4.989